Along these lines, it was shown that LS-OCMB (which is associated with a worse course of MS (16, 26) and higher inflammation demonstrated by augmented NfL values (27) have a protective effect on PML risk in patients receiving natalizumab treatment, independently of age (17, 28). The gene discussed is NEFL; the disease is myeloid sarcoma.